Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MabThera infusions · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TL011 | EXPERIMENTAL | TL011 infusions |
| MabThera | ACTIVE_COMPARATOR | MabThera infusions |
| Name | Type | Description |
|---|---|---|
| TL011, anti CD20, for the treatment of rheumatoid arthritis | BIOLOGICAL | TL011 administered by 2 infusions, 2 weeks apart |
| MabThera infusions | BIOLOGICAL | MabThera, administered by 2 infusions, 2 weeks apart |
Inclusion Criteria: * Adult subjects * Rheumatoid arthritis as defined by the 1987 ACR Classification * Severe active seropositive disease * Inadequate response or intolerance to other DMARDs * Treatment with MTX Exclusion Criteria: * Rheumatic autoimmune disease other than RA * Active infection ...
Top 20 of 28 competitors
MabThera infusions is a monoclonal antibody being developed by Teva Pharmaceutical Industries Limited (TEVA) for the treatment of Rheumatoid Arthritis. It is currently in Phase 1 clinical development as an investigational therapy for this condition.
MabThera infusions is a monoclonal antibody, but its specific molecular target has not been disclosed in the available information. The drug is being studied for its potential role in treating Rheumatoid Arthritis, an autoimmune condition.
MabThera infusions is being developed by Teva Pharmaceutical Industries Limited, a global pharmaceutical company traded on the NYSE under the ticker TEVA. The company is conducting clinical research to evaluate the drug's safety and efficacy in Rheumatoid Arthritis.
MabThera infusions is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, involving 54 participants with severe, active Rheumatoid Arthritis.
MabThera infusions has one completed clinical trial registered as NCT01123070, titled 'TL011 in Severe, Active Rheumatoid Arthritis Patients'. This Phase 1 study enrolled 54 participants across Czechia, Hungary, Italy, Spain, and the United Kingdom, and was a randomized, double-blind, active-controlled trial.
Yes, MabThera infusions is also known as TL011. The completed clinical trial NCT01123070 refers to the drug as TL011, indicating that these names are used interchangeably for the same investigational monoclonal antibody being studied in Rheumatoid Arthritis.